Lineberger Comprehensive Cancer Center, Department of Microbiology and Immunology, School of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.
Proc Natl Acad Sci U S A. 2012 Jul 17;109(29):11818-23. doi: 10.1073/pnas.1205995109. Epub 2012 Jun 29.
The metabolic differences between B-NHL and primary human B cells are poorly understood. Among human B-cell non-Hodgkin lymphomas (B-NHL), primary effusion lymphoma (PEL) is a unique subset that is linked to infection with Kaposi's sarcoma-associated herpesvirus (KSHV). We report that the metabolic profiles of primary B cells are significantly different from that of PEL. Compared with primary B cells, both aerobic glycolysis and fatty acid synthesis (FAS) are up-regulated in PEL and other types of nonviral B-NHL. We found that aerobic glycolysis and FAS occur in a PI3K-dependent manner and appear to be interdependent. PEL overexpress the fatty acid synthesizing enzyme, FASN, and both PEL and other B-NHL were much more sensitive to the FAS inhibitor, C75, than primary B cells. Our findings suggest that FASN may be a unique candidate for molecular targeted therapy against PEL and other B-NHL.
B-NHL 和原代人 B 细胞之间的代谢差异尚未被充分了解。在人类 B 细胞非霍奇金淋巴瘤(B-NHL)中,原发性渗出性淋巴瘤(PEL)是一个独特的亚群,与卡波西肉瘤相关疱疹病毒(KSHV)的感染有关。我们报告称,原代 B 细胞的代谢谱与 PEL 有显著差异。与原代 B 细胞相比,PEL 和其他类型的非病毒性 B-NHL 中,有氧糖酵解和脂肪酸合成(FAS)均上调。我们发现有氧糖酵解和 FAS 以 PI3K 依赖性方式发生,并且似乎相互依赖。PEL 过度表达脂肪酸合成酶 FASN,并且 PEL 和其他 B-NHL 对 FAS 抑制剂 C75 的敏感性均明显高于原代 B 细胞。我们的研究结果表明,FASN 可能是针对 PEL 和其他 B-NHL 的分子靶向治疗的独特候选药物。